Distress, including posttraumatic stress disorder (PTSD) and depression, is associated with lower cognitive function and higher use of medications, including sleep aids, opiate pain relievers, and minor tranquilizers. Whether use of these medications is linked to lower cognitive function, and whether such medication use might partially explain the relationship between distress and cognition remains unclear. Using data from 10,653 women in the Nurses’ Health Study II, we assessed associations between distress and past-month medication use; medication use and cognitive function; and whether medication use mediates the distress–cognitive function relationship.
Methods:
Distress was defined using validated measures of PTSD and depression. To consider possible joint effects of experiencing both forms of distress, we derived a continuous, standardized distress score including symptoms of both PTSD and depression, and a six-level categorical variable indicating the presence/absence of trauma, PTSD, and depression. Past-month medication use was self-reported. Cognitive function was measured with the Cogstate Brief Battery, yielding composite score measures of psychomotor speed/attention and learning/working memory. We fit linear regression models for continuous outcomes, logistic regression for dichotomous outcomes, and conducted causal mediation analysis using a counterfactual framework.
Results:
Higher distress was associated with use of all three medications (e.g., a 1-standard-deviation higher continuous distress score was associated with 1.5 times the adjusted odds of past-month opiate use [95% confidence interval: 1.40, 1.60]). Associations between past-month medication use and cognitive function were mixed.
Conclusion:
We did not find clear evidence of mediation by medication use, suggesting that distress may influence cognitive function via other pathways.
Get full access to this article
View all access options for this article.
References
1.
EliasMF, BeiserA, WolfPA, et al.The preclinical phase of Alzheimer disease: A 22-year prospective study of the Framingham cohort. Arch Neurol, 2000; 57(6):808–813.
2.
RajanKB, AggarwalNT, WilsonRS, et al.Association of cognitive functioning, incident stroke, and mortality in older adults. Stroke, 2014; 45(9):2563–2567.
3.
RobertsonDA, SavvaGM, KennyRA. Frailty and cognitive impairment—A review of the evidence and causal mechanisms. Ageing Res Rev, 2013; 12(4):840–851; doi: 10.1016/j.arr.2013.06.004
4.
LawnRB, JhaSC, LiuJ, et al.The association of posttraumatic stress disorder, depression, and head injury with mid-life cognitive function in civilian women. Depress Anxiety, 2022; 39(3):220–232.
5.
BlockSR, LiberzonI. Attentional processes in posttraumatic stress disorder and the associated changes in neural functioning. Exp Neurol, 2016; 284(Pt B):153–167.
ScottJC, MattGE, WrocklageKM, et al.A quantitative meta-analysis of neurocognitive functioning in posttraumatic stress disorder. Psychol Bull, 2015; 141(1):105–140.
8.
WangTY, WeiHT, LiouYJ, et al.Risk for developing dementia among patients with posttraumatic stress disorder: A nationwide longitudinal study. J Affect Disord, 2016; 205:306–310; doi: 10.1016/j.jad.2016.08.013
9.
RobertsAL, LiuJ, LawnRB, et al.Association of posttraumatic stress disorder with accelerated cognitive decline in middle-aged women. JAMA Netw Open, 2022; 5(6):e2217698.
10.
SumnerJA, HaganK, GrodsteinF, et al.Posttraumatic stress disorder symptoms and cognitive function in a large cohort of middle-aged women. Depress Anxiety, 2017; 34(4):356–366; doi: 10.1002/da.22600
11.
LevineGN, CohenBE, Commodore-MensahY, et al.Psychological health, well-being, and the mind-heart-body connection: A scientific statement from the American Heart Association. Circulation, 2021; 143(10):e763–e783.
12.
O’DonnellCJ, Schwartz LongacreL, CohenBE, et al.Posttraumatic stress disorder and cardiovascular disease: State of the science, knowledge gaps, and research opportunities. JAMA Cardiol, 2021; 6(10):1207–1216.
13.
Kendall-TackettKA. Inflammation, cardiovascular disease, and metabolic syndrome as sequelae of violence against women: The role of depression, hostility, and sleep disturbance. Trauma Violence Abuse, 2007; 8(2):117–126.
14.
HoersterKD, CampbellS, DolanM, et al.PTSD is associated with poor health behavior and greater body mass index through depression, increasing cardiovascular disease and diabetes risk among U.S. veterans. Prev Med Rep, 2019; 15:100930.
15.
VerdelhoA, MadureiraS, MoleiroC, et al.; LADIS Study. Depressive symptoms predict cognitive decline and dementia in older people independently of cerebral white matter changes: The LADIS study. J Neurol Neurosurg Psychiatry, 2013; 84(11):1250–1254.
16.
GuanT, ZhangC, ZouX, et al.The influence of alcohol consumption, depressive symptoms and sleep duration on cognition: Results from the China Health and Retirement Longitudinal Study. Int J Environ Res Public Health, 2022; 19(19).
17.
LawsKR, IrvineK, GaleTM. Sex differences in cognitive impairment in Alzheimer’s disease. World J Psychiatry, 2016; 6(1):54–65.
18.
KoenenKC, RatanatharathornA, NgL, et al.Posttraumatic stress disorder in the World Mental Health Surveys. Psychol Med, 2017; 47(13):2260–2274.
19.
CarterMW, YangBK, DavenportM, et al.Increasing rates of opioid misuse among older adults visiting emergency departments. Innov Aging, 2019; 3(1):igz002–i13.
20.
TaylorMH, GrossbergGT. The growing problem of illicit substance abuse in the elderly: A review. Prim Care Companion CNS Disord, 2012; 14(4).
21.
MawandaF, WallaceRB, McCoyK, et al.PTSD, psychotropic medication use, and the risk of dementia among US veterans: A retrospective cohort study. J Am Geriatr Soc, 2017; 65(5):1043–1050.
22.
SchulkensJEM, DeckersK, JenniskensM, et al.The effects of selective serotonin reuptake inhibitors on memory functioning in older adults: A systematic literature review. J Psychopharmacol, 2022; 36(5):578–593.
23.
López-MartínezAE, Reyes-PérezÁ, Rocío Serrano-IbáñezE, et al.Chronic pain, posttraumatic stress disorder, and opioid intake: A systematic review. World J Clin Cases, 2019; 7(24):4254–4269.
24.
LoweSR, SampsonL, YoungMN, et al.Alcohol and nonmedical prescription drug use to cope with posttraumatic stress disorder symptoms: An analysis of hurricane sandy survivors. Subst Use Misuse, 2017; 52(10):1348–1356.
25.
DabbsC, WatkinsEY, FinkDS, et al.Opiate-related dependence/abuse and PTSD exposure among the active-component U.S. military, 2001 to 2008. Mil Med, 2014; 179(8):885–890.
26.
FishbainDA, PulikalA, LewisJE, et al.Chronic pain types differ in their reported prevalence of post-traumatic stress disorder (PTSD) and there is consistent evidence that chronic pain is associated with PTSD: An evidence-based structured systematic review. Pain Med, 2017; 18(4):711–735.
27.
ZipfelS, TesarzJ, JunneF, et al.Prevalence of posttraumatic stress disorder in persons with chronic pain: A meta-analysis. Front Psychiatry, 2017; 8. Available from: www.frontiersin.org
JakupcakM, MichaelS, CookJ, et al.Anxiety sensitivity and depression: Mechanisms for understanding somatic complaints in veterans with posttraumatic stress disorder. J Trauma Stress, 2006; 19(4):471–479.
30.
HarveyAG, JonesC, SchmidtDA. Sleep and posttraumatic stress disorder: A review. In: Clinical Psychology Review. Vol. 23. Elsevier Inc.; 2003; pp. 377–407.
31.
Van LiemptS. Sleep disturbances and PTSD: A perpetual circle? Eur J Psychotraumatol, 2012; 3.
32.
PaskS, Dell’OlioM, MurtaghFEM, et al.The effects of opioids on cognition in older adults with cancer and chronic noncancer pain: A systematic review. J Pain Symptom Manage, 2020; 59(4):871–893.e1.
33.
BaldacchinoA, BalfourDJK, PassettiF, et al.Neuropsychological consequences of chronic opioid use: A quantitative review and meta-analysis. Neurosci Biobehav Rev, 2012; 36(9):2056–2068.
34.
LeeJE, JuYJ, ChunKH, et al.The frequency of sleep medication use and the risk of Subjective Cognitive Decline (SCD) or SCD with functional difficulties in elderly individuals without dementia. J Gerontol A Biol Sci Med Sci, 2020; 75(9):1693–1698.
35.
ZhangY, ZhouX, MeranusDH, et al.Benzodiazepine use and cognitive decline in elderly with normal cognition. Alzheimer Dis Assoc Disord, 2016; 30(2):113–117.
36.
WrightRM, RoumaniYF, BoudreauR, et al.; Health, Aging and Body Composition Study. Effect of central nervous system medication use on decline in cognition in community-dwelling older adults: Findings from the health, aging and body composition study. J Am Geriatr Soc, 2009; 57(2):243–250.
37.
DublinS, WalkerRL, GraySL, et al.Prescription opioids and risk of dementia or cognitive decline: A prospective cohort study. J Am Geriatr Soc, 2015; 63(8):1519–1526.
38.
ShihHI, LinCC, TuYF, et al.An increased risk of reversible dementia may occur after zolpidem derivative use in the elderly population: A population-based case-control study. Medicine, 2015; 94(17):e809.
39.
BeracocheaD. Anterograde and retrograde effects of benzodiazepines on memory. ScientificWorldJournal, 2006; 6:1460–1465.
40.
GallacherJ, ElwoodP, PickeringJ, et al.Benzodiazepine use and risk of dementia: Evidence from the Caerphilly Prospective Study (CaPS). J Epidemiol Community Health, 2012; 66(10):869–873; doi: 10.1136/jech-2011-200314
41.
HanlonJT, HornerRD, SchmaderKE, et al.Benzodiazepine use and cognitive function among community-dwelling elderly. Clin Pharmacol Ther, 1998; 64(6):684–692; doi: 10.1016/S0009-9236%2898%2990059-5
42.
SampsonL, JhaSC, RobertsAL, et al.Trauma, post-traumatic stress disorder, and treatment among middle-aged and older women in the Nurses’ Health Study II. Am J Geriatr Psychiatry, 2022; 30(5):588–602.
43.
FredricksonJ, MaruffP, WoodwardM, et al.Methods in neuroepidemiology evaluation of the usability of a brief computerized cognitive screening test in older people for epidemiological studies. Neuroepidemiology, 2010; 34(2):65–75.
44.
KoyamaAK, HaganKA, OkerekeOI, et al.Evaluation of a self-administered computerized cognitive battery in an older population. Neuroepidemiology, 2015; 45(4):264–272.
45.
MorganCA, HazlettG, WangS, et al.Symptoms of dissociation in humans experiencing acute, uncontrollable stress: A prospective investigation. Am J Psychiatry, 2001; 158(8):1239–1247.
AndresenEM, MalmgrenJA, CarterWB, et al.Screening for depression in well older adults: Evaluation of a short form of the CES-D (Center for Epidemiologic Studies Depression Scale). Am J Prev Med, 1994; 10(2):77–84.
50.
McmanusD, PipkinSS, WhooleyMA. Screening for depression in patients with coronary heart disease (Data from the Heart and Soul Study). Am J Cardiol, 2005; 96(8):1076–1081.
51.
PlassmanBL, WilliamsJW, BurkeJR, et al.Systematic review: Factors associated with risk for and possible prevention of cognitive decline in later life. Ann Intern Med, 2010; 153(3):182–193.
52.
MaruffP, LimYY, DarbyD, et al.; AIBL Research Group. Clinical utility of the Cogstate Brief Battery in identifying cognitive impairment in mild cognitive impairment and Alzheimer’s disease. BMC Psychol, 2013; 1(1):30–11; doi: 10.1186/2050-7283-1-30
53.
LimYY, EllisKA, HarringtonK, et al.Use of the CogState Brief Battery in the assessment of Alzheimer’s disease related cognitive impairment in the Australian Imaging, Biomarkers and Lifestyle (AIBL) study. J Clin Exp Neuropsychol, 2012; 34(4):345–358.
54.
HammersD, SpurgeonE, RyanK, et al.Validity of a brief computerized cognitive screening test in dementia. J Geriatr Psychiatry Neurol, 2012; 25(2):89–99; doi: 10.1177/0891988712447894
55.
RobertsAL, Pascual-LeoneA, SpeizerFE, et al.Exposure to American football and neuropsychiatric health in former national football league players: Findings from the football players health study. Am J Sports Med, 2019; 47(12):2871–2880.
56.
AdamsRS. Traumatic brain injury and opioid use: Additional evidence supporting the “perfect storm” of cascading vulnerabilities. J Head Trauma Rehabil, 2021; 36(5):303–309.
57.
BoschlooL, VogelzangsN, SmitJH, et al.Comorbidity and risk indicators for alcohol use disorders among persons with anxiety and/or depressive disorders: Findings from the Netherlands Study of Depression and Anxiety (NESDA). J Affect Disord, 2011; 131(1–3):233–242.
58.
VanderWeeleTJ, VansteelandtS. Conceptual issues concerning mediation, interventions and composition. Statistics and Its Inference, 2009; 2(4):457–468.
59.
ValeriL, VanderWeeleTJ. Mediation analysis allowing for exposure-mediator interactions and causal interpretation: Theoretical assumptions and implementation with SAS and SPSS macros. Psychol Methods, 2013; 18(2):137–150.
ShiB, ChoiratC, ValeriL. CMAverse: A Suite of Functions for Causal Mediation Analysis. Available from: https://bs1125.github.io/CMAverse/ [Last accessed: May31, 2023].
62.
KimmelSE, SchellemanH, BerlinJA, et al.The effect of selective serotonin re-uptake inhibitors on the risk of myocardial infarction in a cohort of patients with depression. Br J Clin Pharmacol, 2011; 72(3):514–517.
63.
McDonaldDC, CarlsonK, IzraelD. Geographic variation in opioid prescribing in the U.S. J Pain, 2012; 13(10):988–996.
PradoCE, WattS, CroweSF. A meta-analysis of the effects of antidepressants on cognitive functioning in depressed and non-depressed samples. Neuropsychol Rev, 2018; 28(1):32–72; doi: 10.1007/s11065-018-9369-5
66.
MorarosJ, NwankwoC, PattenSB, et al.The association of antidepressant drug usage with cognitive impairment or dementia, including Alzheimer disease: A systematic review and meta-analysis. Depress Anxiety, 2017; 34(3):217–226; doi: 10.1002/da.22584
67.
HaleJM, SchneiderDC, MehtaNK, et al.Cognitive impairment in the U.S.: Lifetime risk, age at onset, and years impaired. SSM Popul Health, 2020; 11:100577.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
